Purevax Recombinant Felv - 1555.R4

Verify with FDA CVM →

70 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
70
Total Reports
15
Deaths Reported
2140.0%
Death Rate

Active Ingredients

Purevax Recombinant Felv - 1555.R4

Administration Routes

SubcutaneousUnknown

Species Affected

Cat 70

Most Affected Breeds

Domestic Shorthair 43
Domestic Mediumhair 8
Domestic Longhair 7
Siamese 4
Cat (unknown) 3
Abyssinian cat 1
Chartreuse 1
Bengal 1
Maine Coon 1
Cat (other) 1

Most Reported Reactions

Vomiting 16
Fever 12
Lethargy (see also Central nervous system depression in 'Neurological') 11
Lethargy (see also Central nervous system depression in Neurological) 11
Not eating 10
Other abnormal test result NOS 10
Anorexia 10
Death 8
Neutrophilia 8
Death by euthanasia 7
Weight loss 6
Hyperglycaemia 6

Outcome Breakdown

Recovered/Normal
25 (35.7%)
Outcome Unknown
23 (32.9%)
Died
8 (11.4%)
Euthanized
7 (10.0%)
Ongoing
7 (10.0%)

Data Summary

Metric Value
Total adverse event reports 70
Reports involving death 15
Case-fatality rate (reported events) 2140.0%
Distinct species in reports 1
Distinct breeds in reports 10
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Purevax Recombinant Felv - 1555.R4 Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 70 adverse event reports referencing Purevax Recombinant Felv - 1555.R4, including 15 reports in which the animal died — a 2140.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Purevax Recombinant Felv - 1555.R4. Reported administration routes include Subcutaneous, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Purevax Recombinant Felv - 1555.R4 reports are Cat (70 reports), with Cat accounting for the largest share. Within those species, Domestic Shorthair (43), Domestic Mediumhair (8), Domestic Longhair (7) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Purevax Recombinant Felv - 1555.R4 are Vomiting (16), Fever (12), Lethargy (see also Central nervous system depression in 'Neurological') (11), Lethargy (see also Central nervous system depression in Neurological) (11). Of the 70 reports with a coded outcome, Recovered/Normal is the leading category at 35.7%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Purevax Recombinant Felv - 1555.R4.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial